Notice of 2026 first extraordinary general meeting
Filed with HKEX · Stock code 2185 · · 3 pages · English
Summary by 6ix AI
The meeting will address the appointment of a new independent non-executive director and outline registration and voting procedures for shareholders. Shareholders must ensure their eligibility to attend by registering their shares before the specified deadline. Voting at the meeting will be conducted by poll, as required by the stock exchange rules.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Shanghai Bio-Heart Biological Technology Co., Ltd. on 6ix
Earlier from Shanghai Bio-Heart Biological Technology
- Announcement pursuant to rule 13.51B(2) of the listing rules
- Voluntary announcement strategic cooperation agreement with shanghai shenqi medical technology co., ltd. to advance the commercialisation of the bioheart bioabsorbable rapamycin-eluting coronary stent system
- Articles of association
Later from Shanghai Bio-Heart Biological Technology
- Proposed appointment of independent non-executive director; and (2) notice of 2026 first extraordinary general meeting
- Proxy form for use at the 2026 first extraordinary general meeting to be held on October 9, 2026
- 2026 Interim report
- Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2026
- (1) Poll results of the 2026 first extraordinary general meeting held on October 9, 2026; (2) resignation of independent non-executive director; (3) appointment of independent non-executive director; and (4) change of composition of board committees
Follow Shanghai Bio-Heart Biological Technology into a list and get an email when it puts out news.
Follow Shanghai Bio-Heart Biological Technology